A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508126-95-00

Acronym

AKIR001

Enrollment

Registered

2024-09-12

Start date

2025-02-10

Completion date

Unknown

Last updated

2025-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and non-small cell lung cancer., squamous cell carcinoma originating from head and neck region, such as advanced thyroid cancer, The target population of the trial consists of patients with locally advanced irresectable or metastatic solid malignancies, vulvar or cervix squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Sweden

Outcome results